个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Honghong[1] ; Wan Yang[2] ; Wang Hongsheng[1] ; Cai Jiaoyang[3] ; Yu Jie[4] ; Hu Shaoyan[5] ; Fang Yongjun[6] ; Gao Ju[7] ; Jiang Hua[8] ; Yang Minghua[9] ; Liang Changda[10] ; Jin Runming[11] ; Tian Xin[12] ; Ju Xiuli[13] ; Hu Qun[14] ; Jiang Hui[15] ; Li Zhifan[16] ; Wang Ningling[17] ; Sun Lirong[18] ; Leung Alex W K[19] ; Wu Xuedong[20] ; Qian Xiaowen[1] ; Qian Maoxiang[1] ; Li Chi-Kong[19] ; Yang Jun[21,22,23] ; Tang Jingyan[3] ; Zhu Xiaofan[2] ; Shen Shuhong[3,*3] ; Zhang Li[2,*4] ; Pui Ching-Hon[21,22,23,*2] ; Zhai Xiaowen[1,*1] ;
机构： [1]Department of Hematology/Oncology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China. [2]Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp [3]Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp [4]Peking Union Medical College, Tianjin, China. [3]Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp [6]Oncology, Shanghai, China. [4]Department of Hematology/Oncology, Chongqing Medical University Affiliated Children's Hospital, Chongqing, China. [5]Department of Hematology/Oncology, Children's Hospital of Soochow University, Suzhou, China. [6]Department of Hematology/Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China. [7]Department of Pediatrics, West China Second University Hospital, Sichuan University, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, Chengdu, China. [8]Department of Hematology/Oncology, Guangzhou Women and Children's Medical Center, Guangzhou, China. [9]Department of Pediatrics, Xiangya Hospital Central South University, Changsha, China. [10]Department of Hematology/Oncology, Jiangxi Provincial Children's Hospital, Nanchang, China. [11]Department of Pediatrics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [12]Department of Hematology/Oncology, KunMing Children's Hospital, Kunming, China. [13]Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China. [14]Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [15]Department of Hematology/Oncology, Children's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China. [16]Department of Hematology/Oncology, Xi'an Northwest Women's and Children's Hospital, Xi'an, China. [17]Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Hefei, Anhui, China. [18]Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, China. [19]Department of Pediatrics, Hong Kong Children's Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China. [20]Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China. [21]Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [22]Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [23]Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
出处：
DOI： 10.1002/cncr.34741
ISSN：

关键词： acute lymphoblastic leukemia event‐free survival prognostic factor TCF3::PBX1

摘要：
Contemporary risk-directed treatment has improved the outcome of patients with acute lymphoblastic leukemia (ALL) and TCF3::PBX1 fusion. In this study, the authors seek to identify prognostic factors that can be used to further improve outcome.The authors studied 384 patients with this genotype treated on Chinese Children's Cancer Group ALL-2015 protocol between January 1, 2015 and December 31, 2019. All patients provisionally received intensified chemotherapy in the intermediate-risk arm without prophylactic cranial irradiation; those with high minimal residual disease (MRD) ≥1% at day 46 (end) of remission induction were candidates for hematopoietic cell transplantation.The overall 5-year event-free survival was 84.4% (95% confidence interval [CI], 80.6-88.3) and 5-year overall survival 88.9% (95% CI, 85.5-92.4). Independent factors associated with lower 5-year event-free survival were male sex (80.4%, [95% CI, 74.8-86.4] vs. 88.9%, [95% CI, 84.1-93.9] in female, p = .03) and positive day 46 MRD (≥0.01%) (62.1%, [95% CI, 44.2-87.4] vs. 87.1%, [95% CI, 83.4-90.9] in patients with negative MRD, p < .001). The presence of testicular leukemia at diagnosis (n = 10) was associated with particularly dismal 5-year event-free survival (33.3% [95% CI, 11.6-96.1] vs. 83.0% [95% CI, 77.5-88.9] in the other 192 male patients, p < .001) and was an independent risk factor (hazard ratio [HR], 5.7; [95% CI, 2.2-14.5], p < .001).These data suggest that the presence of positive MRD after intensive remission induction and testicular leukemia at diagnosis are indicators for new molecular therapeutics or immunotherapy in patients with TCF3::PBX1 ALL.© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

基金：
National Natural Science Foundation of China, Grant/Award Numbers: 81670136, 82141125; Science and Technology Commission of Shanghai Municipality, Grant/ Award Number: 21Y31900302; VIVA China Children's Cancer Foundation; Shanghai Sailing Program, Science and Technology Commission of Shanghai Municipality, Grant/ Award Number: 20YF1403000; Cyrus Tang Foundation, Grant/Award Number: ZSBK0070; Shanghai Fudan University Education Development Foundation, Grant/ Award Number: ZSBK0046; Shanghai Hospital Development Center, Grant/Award Number: SHDC12019121; American Lebanese Syrian Associated Charities
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Hematology/Oncology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Hematology/Oncology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China. [2]Department of Pediatrics, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology &amp [3]Blood Diseases Hospital, Chinese Academy of Medical Sciences &amp [3]Department of Hematology/Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology &amp [21]Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [22]Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [23]Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [*1]Department of Hematology/Oncology, Children's Hospital of Fudan University, 399 Wanyuan Road, Shanghai 201102, China. [*2]Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA. [*3]Department of Hematology/Oncology, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, 1678 Dongfang Road, Shanghai 200127, China [*4]Department of Pediatrics, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin 300020, China.
推荐引用方式(GB/T 7714)：
Zhang Honghong,Wan Yang,Wang Hongsheng,et al.Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study[J].CANCER.2023,129(11):1691-1703.doi:10.1002/cncr.34741.
APA：
Zhang Honghong,Wan Yang,Wang Hongsheng,Cai Jiaoyang,Yu Jie...&Zhai Xiaowen.(2023).Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.CANCER,129,(11)
MLA：
Zhang Honghong,et al."Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study".CANCER 129..11(2023):1691-1703

相关文献

[1]Pediatric acute lymphoblastic leukemia with t(1;19)/TCF3-PBX1 in Taiwan [2]Prognostic significance of steroid response in pediatric acute lymphoblastic leukemia: The CCCG-ALL-2015 study [3]Outcome of infants with acute lymphoblastic leukemia treated with the Chinese Children's Cancer Group Acute Lymphoblastic Leukemia 2015 study protocol [4]Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. [5]Prognostic Factors for CNS Control in Children with Acute Lymphoblastic Leukemia Treated Without Cranial Irradiation. [6]A new insight into acute lymphoblastic leukemia in children: influences of changed intestinal microfloras. [7]Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. [8]ARID5B Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia. [9]Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review [10]Age-related differences of genetic susceptibility to patients with acute lymphoblastic leukemia.

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号